References
- Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
- Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–3947.
- Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005;23:474–481.
- Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789–1796.
- Bibeau F, Crapez E, Di Fiore F, et al. Association of FcγRIIa and FcγRIIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan. J Clin Oncol 2009;27:1122–1129.
- Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001;276:6591–6604.
- Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733–26740.
- Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 2004;336:1239–1249.
- Goede V, Kirsten F, Bushe R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101–1110.
- Ganjoo KN, de Vos S, Pohlman BL, et al. Phase study of ocaratuzumab, an Fc-engineeered humanized anti-CD20 monoclonal antibody, in patients with low affinity FcγRIIIa with previously treated follicular lymphoma. Leuk Lymphoma 2015;56:42–48.
- Forero-Terres A, de Vos S, Pohlman BL, et al. Results of phase I study of AME-133v (LY2469298) an FC-engineering humanized monoclonal anti-CD20 antibody, in FcgRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012;18:1395–1403.
- Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940–3947.
- Dave TA, Grillo-Lopez AJ, Withe CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma; safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135–3143.